<table>
<thead>
<tr>
<th>Protease Inhibitors</th>
<th>NNRTIs</th>
<th>NRTIs</th>
<th>Integrate Inhibitors</th>
<th>Entry &amp; Attachment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atazanavir alone</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atazanavir/ritonavir</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Darunavir/ritonavir</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Darunavir/ritonavir</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Darunavir/ritonavir</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lopinavir/ritonavir</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**NNRTIs**

- Dolutegravir/Rilpivirine
- Darunavir/cobi/FTC/TAF
- Darunavir/cobi/FTC/TAF
- Darunavir/ritonavir

**NRTIs**

- Abacavir (ABC)
- Emtricitabine (FTC)
- Emtricitabine/TAF
- Lamivudine (3TC)
- Tenofovir-DP (TDF)
- Zidovudine (AZT/3TC)

**Integrate Inhibitors**

- Bictegravir/TAF
- Cabotegravir P/EPC
- Cabotegravir/Rilpivirine
- Dolugrtovir
- Dolugrtovir/ABC/3TC

**Entry & Attachment**

- Entefuviride (ENF, T20)
- Fostemsavir (FTR)
- Balituzumab (IBA)
- Maraviroc (MVC)

---

**Key to symbols**

- These drugs should not be coadministered.
- Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration.
- Potential interaction likely to be of weak intensity - additional action/monitoring or dosage adjustment is unlikely to be required.
- No clinically significant interaction expected.

Where advice differs between countries, or between boosted and unboosted regimens, the charts reflect the more cautious option.

---

**Key to abbreviations**

- ATV: Atazanavir (Reyataz®)
- ATV/CR: Atazanavir/Cobicistat (Evexia®)
- ATV/cobi: Atazanavir/Cobicistat (Evexia®)
- DRV/CR: Darunavir/Cobicistat (Reyataz® + Maraviroc®)
- DRV/cobi: Darunavir/Cobicistat (Reyataz® + Maraviroc®)
- DOR: Dolutegravir (Retravir®)
- DRV/3TC: Darunavir/Lamivudine + Tenofovir-DF (Dolutegravir + Tenofovir-DF)
- EFV: Etravirine (Intelence®)
- EFV/3TC: Etravirine/Lamivudine + Tenofovir-DF (Etravirine + Tenofovir-DF)
- FTC/TAF: Emtricitabine + Tenofovir-DF (TDF/FTC)
- FTI: Tenofovir alafenamide (TDF)
- FTC: Emtricitabine (Emtriva®)
- TDF: Tenofovir disoproxil fumarate (Viread®)
- D4T: D4T (D Guidelines)
- DRV: Darunavir (Reyataz®)
- DRV/3TC: Darunavir/Cobicistat (Reyataz® + Maraviroc®)
- FTC/TDF: Emtricitabine + Tenofovir disoproxil fumarate (TDF/FTC)
- EFV/3TC/TDF: Etravirine/Lamivudine + Tenofovir disoproxil fumarate (Dolutegravir + Tenofovir-DF)
- RAL: Raltegravir (Isentress®)

---

© Liverpool Drug Interactions Group, University of Liverpool, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its agents or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise however or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.